DAPT Score Calculator
The DAPT score helps clinicians decide whether to continue dual antiplatelet therapy (thienopyridine plus aspirin) beyond 12 months after percutaneous coronary intervention (PCI) with stent placement. Enter patient age and eight clinical and procedural factors. A score of 2 or higher suggests prolonged DAPT is likely to provide net ischemic benefit; a score below 2 suggests aspirin alone is the safer choice. The tool implements the Yeh et al. 2016 JAMA scoring algorithm exactly.
What is the DAPT score?
The Dual Antiplatelet Therapy (DAPT) score is a validated clinical decision tool that predicts the net benefit or harm of continuing a thienopyridine (such as clopidogrel, prasugrel, or ticagrelor) in addition to aspirin beyond 12 months after percutaneous coronary intervention (PCI) with coronary stent placement. It was developed and validated by Robert W. Yeh and colleagues from the DAPT study investigators and published in JAMA in 2016. The score ranges from -2 to 10 and is built from nine variables covering patient demographics, cardiac history, and procedural details. A score of 2 or above indicates that the reduction in ischemic events (myocardial infarction and stent thrombosis) is expected to outweigh the associated increase in bleeding risk with extended DAPT. A score below 2 indicates the opposite: that continuing thienopyridine therapy is more likely to produce a net harm from bleeding.
How the score is calculated
The DAPT score assigns points to nine variables. Age carries a negative contribution because older patients experience higher baseline bleeding risk and a smaller relative ischemic benefit from extended DAPT: age 75 years or older subtracts 2 points, age 65 to 74 subtracts 1 point, and age under 65 contributes 0 points. Six variables each contribute 1 point when present: current or recent cigarette smoking, diabetes mellitus, myocardial infarction at the time of the qualifying PCI, prior history of PCI or MI, use of a paclitaxel-eluting stent (TAXUS), and placement of a stent with a diameter less than 3 mm. Two high-weight variables each contribute 2 points: congestive heart failure or a left ventricular ejection fraction below 30%, and PCI performed on a saphenous vein graft. The points are summed to give a total between -2 and 10. The 2016 DAPT study used this score prospectively to show that patients with a total of 2 or more had substantially lower event rates when randomized to continued thienopyridine therapy compared to those who received aspirin alone.
Clinical context and guideline use
Coronary stenting with drug-eluting stents reduces restenosis but introduces a long-term risk of stent thrombosis, a potentially fatal complication. DAPT with aspirin and a P2Y12 inhibitor reduces stent thrombosis and MI risk but increases gastrointestinal and other major bleeding. For many years guidelines recommended 12 months of DAPT as the default duration, but newer evidence confirmed that some patients benefit from extending therapy while others do not. The 2016 ACC/AHA focused update on DAPT duration endorsed the DAPT score as a tool to guide this individual-level decision. A score of 2 or higher supports a class IIb recommendation for extending therapy to 30 months; a score below 2 supports stopping at 12 months. The score should not replace clinical judgment and should be interpreted alongside patient preferences, bleeding history, current medications, and the type of stent used. Modern drug-eluting stents have lower late-stent-thrombosis rates than first-generation paclitaxel stents, so the absolute benefit of prolonged DAPT continues to evolve with device technology.
Limitations of the DAPT score
The DAPT score has several important limitations. It was derived primarily from data on first-generation drug-eluting stents and may overestimate the benefit of prolonged DAPT with newer-generation stents that have lower thrombosis rates. The score assigns particular weight to paclitaxel-eluting stents, which are now rarely used, so many patients will see minimal contribution from that variable. The score does not incorporate renal function, body weight, bleeding history, or anticoagulation use, each of which strongly influences individual bleeding risk. The PRECISE-DAPT score, developed in Europe with a different dataset, incorporates haemoglobin, white blood cell count, age, creatinine, and prior bleeding to predict bleeding specifically, and is often used alongside the DAPT score. The two scores sometimes give conflicting guidance, and neither fully replaces the clinical conversation about risks and benefits for each patient.
DAPT Score variables and point values
| Variable | Condition | Points |
|---|---|---|
| Age | >= 75 years | -2 |
| Age | 65-74 years | -1 |
| Age | < 65 years | 0 |
| Cigarette smoking | Current or recent | +1 |
| Diabetes mellitus | Present | +1 |
| MI at presentation | Yes (STEMI or NSTEMI) | +1 |
| Prior PCI or prior MI | Present | +1 |
| Paclitaxel-eluting stent | Used at qualifying PCI | +1 |
| Stent diameter < 3 mm | Any stent placed | +1 |
| CHF or LVEF < 30% | Present | +2 |
| Vein graft stent | Saphenous vein graft PCI | +2 |
Scoring derived from Yeh et al., JAMA 2016. Validated in 11,648 patients from the DAPT trial and 8,136 from the PROTECT trial.
Frequently asked questions
What does a DAPT score of 2 or higher mean?
A DAPT score of 2 or above indicates that the patient is in a high-ischemic-benefit, low-relative-bleeding-risk category where continuing thienopyridine therapy in addition to aspirin beyond 12 months after PCI is expected to produce net clinical benefit. In the original Yeh et al. validation, high-score patients had a statistically significant reduction in myocardial infarction and stent thrombosis without a proportionate increase in major bleeding when DAPT was continued to 30 months.
What happens for a DAPT score below 2?
A score below 2 suggests that aspirin monotherapy is the safer choice after the initial 12-month DAPT period. In this group, prolonged thienopyridine use was associated with an increase in bleeding events that was not offset by a clinically meaningful reduction in ischemic events. Guidelines support stopping the P2Y12 inhibitor at or after 12 months in these patients, while continuing aspirin indefinitely.
Why does older age reduce the DAPT score?
Older age subtracts points because elderly patients face substantially higher absolute risks of gastrointestinal and intracranial bleeding with antiplatelet therapy, while their relative reduction in stent thrombosis is smaller than in younger patients. Age 75 or older carries the maximum penalty of -2 points, and age 65-74 carries -1 point, reflecting this graded increase in bleeding susceptibility.
Which thienopyridines are covered by the DAPT score?
The original DAPT trial used clopidogrel or prasugrel as the thienopyridine. The score has been applied in practice to ticagrelor as well, though ticagrelor is technically a cyclopentyl-triazolo-pyrimidine rather than a thienopyridine. The decision to extend any P2Y12 inhibitor beyond 12 months should incorporate the specific agent used, its bleeding profile, and whether the patient has tolerated it without major events during the initial 12-month period.
Should the DAPT score be used alone to make the treatment decision?
No. The DAPT score is a decision-support tool, not a standalone protocol. The 2016 ACC/AHA guidelines recommend using it alongside clinical judgment and shared decision-making with the patient. Factors not captured in the score, such as renal function, anticoagulation for atrial fibrillation, active cancer, recent surgery, and patient preferences around bleeding versus clotting risk, may be decisive. For patients at high bleeding risk the PRECISE-DAPT score can complement the DAPT score by quantifying the bleeding-specific hazard.
Is the DAPT score still relevant for modern drug-eluting stents?
The score retains clinical utility but should be applied with awareness that it was validated in an era dominated by first- and second-generation drug-eluting stents. Newer thin-strut, biocompatible-polymer stents have lower late-thrombosis rates, which reduces the absolute ischemic benefit of prolonged DAPT for all patients. For those implanted with the latest-generation stents the decision to extend DAPT should weigh that the absolute risk reduction may be smaller than the original score-derived estimates.
Sources
- Yeh RW et al. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016;315(16):1735-1749.
- Levine GN et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. J Am Coll Cardiol. 2016;68(10):1082-1115.